Peptides DB
Research-centric peptide and protocol reference hub
Study 15 of 47NAD+ (Nicotinamide Adenine Dinucleotide) literaturebiorxiv-preprint · Observational2026

Mechanisms of apoptosis in colon cancer cells induced by IDO1 inhibitor and irradiation: A metabolomic study

The study found that IDO1 inhibition combined with radiation increased apoptosis in colon cancer cells while decreasing NAD+ levels, but the clinical implications of these findings are uncertain.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpus
17
Preclinical
23
Observational · this one
1
Open-label
1
Randomised
5
Reviews

Summary and findings

This study investigated the effects of IDO1 inhibition and radiation on apoptosis in colon cancer cells, specifically examining the role of NAD+. The combination treatment showed an increase in apoptosis rates and a decrease in NAD+ levels. No therapeutic claims are made.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
NAD+ levels decreased by additional 1-MT in radiated Colon26 cells (452 vs. 1027 nmol/g, p = 0.0495)2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

Abstract Background: Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the conversion of tryptophan to kynurenine, promoting tumor progression via immune suppression and activation of the Wnt/β-catenin pathway. As the activation of kynurenine pathway also produces key metabolites such as nicotinamide adenine dinucleotide (NAD + ), its inhibition may influence tumor cell metabolism and contribute to anti-tumor effects. This study investigated the mechanisms underlying the combined effects of IDO1 inhibition and radiation (Rad) on colon cancer cells, with a focus on metabolic alterations. Methods: Colon26 murine colon cancer cells were treated with an IDO1 inhibitor, 1-methyltryptophan (1-MT), Rad (10 Gy/10 fractions), or both. Apoptosis was evaluated in cultured cells and subcutaneous tumors. Apoptosis-related proteins in cultured Colon26 cells treated with 1-MT and/or Rad were evaluated by Western blot analysis. Metabolome analysis assessed intracellular changes in metabolites including NAD + of kynurenine pathways caused by these treatments. The additional effect of β-nicotinamide mononucleotide (NMN) was evaluated. Results: Combination treatment with 1-MT and Rad increased apoptosis compared to Rad alone in vitro (7.0% vs. 5.5%, p = 0.0495) and in vivo (0.19% vs. 0.13%, p = 0.025). Western blotting showed elevations of cleaved caspase 3, 8, and 9 by dual treatments. NAD + levels decreased by additional 1-MT in radiated Colon26 cells (452 vs. 1027 nmol/g, p = 0.0495). Supplementation with NMN (500 μM) restored NAD + levels and suppressed apoptosis in cells treated with 1-MT and Rad. Conclusions: IDO1 inhibition enhanced Rad-induced apoptosis in Colon26 cell through NAD + depletion. Targeting NAD + synthesis may represent a therapeutic approach in colorectal cancer.

Elsewhere in the NAD+ (Nicotinamide Adenine Dinucleotide) corpus

CBioactive vitamin E-NAD<sup>+</sup> conjugate nanoparticles for osteoarthritis management via simultaneous suppression of inflammation and oxidative stress.Biomaterials · 2026 · Not reported in abstract.AnimalBNAD metabolism mediates a sex-specific protection against early life infectionsbiorxiv-preprint · 2026 · Higher birth NAD levels in females were associated with reduced infection burdens during the first 3 years of life.HumanBControl-referenced bacterial bioluminescence reveals a two-axis salivary response phenotype in benign and malignant breast disease.Talanta · 2026 · n=200 · Not reported in abstract.HumanBGenetic modulation of NAD(P)H homeostasis reveals distinct redox-coupled metabolic vulnerabilities.Nature metabolism · 2026 · Not reported in abstract.HumanDA context-dependent framework for targeting NAD metabolism in cancer.Cell metabolism · 2026reviewBPart 1 of a 2-part, open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 3 consecutive days of intramuscular and subcutaneous injectionsbiorxiv-preprint · 2026 · 9.97% average daily increase in NAD+ for 100 mg IM.Human